Member access

4-Traders Homepage  >  Shares  >  Nyse  >  Johnson & Johnson    JNJ   US4781601046

JOHNSON & JOHNSON (JNJ)

209
SummaryQuotesChart AnalysisNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 

Johnson & Johnson : J&J Cancer Drug Zytiga Now Backed For Publicly Funded Use In UK

05/16/2012 | 05:11am US/Eastern
Recommend:
0

The U.K.'s health-care cost-effectiveness regulator Wednesday reversed an earlier decision and approved the publicly funded use of Johnson & Johnson's (JNJ) prostate-cancer pill Zytiga, after the U.S. company cut its price further.

Also known as abiraterone, Zytiga removes the prostate cancer tumor's supply of testosterone, preventing it from growing further and potentially extending a patient's life by more than three months. The medicine was rejected for use in the U.K. in February on grounds its terms of use wouldn't offer value for money.

Andrew Dillon, chief executive of the U.K.'s National Institute for Health and Clinical Excellence, or NICE, Wednesday said the manufacturer subsequently submitted fresh information, including a revised patient access scheme containing a deeper price discount to the National Health Service and more information about which patients would most benefit from its use and how many patients could receive the drug.

"These factors enabled the committee to revise its preliminary recommendation and now recommend the drug for use on the NHS," Dillon said in a statement. "It is an effective treatment, potentially extending life by more than three months, and it also allows patients to be treated at home as it can be taken orally."

Abiraterone costs GBP2,930 for a 30-day supply of 120 tablets. NICE didn't specify the size of the price cut offered by Johnson & Johnson.

Zytiga was approved by U.S. and European drug regulators last year. It is set to generate peak-year sales of $910 million.

-By Sten Stovall, Dow Jones Newswires; +44 207 842 9292; sten.stovall@dowjones.com

Recommend :
0
React to this article
Latest news on JOHNSON & JOHNSON
2h ago JOHNSON & JOHNSON : J&J withdraws fibroid treatment device from market
13h ago JOHNSON & JOHNSON : Power Morcellator Lawyers at Parilman & Associates Alert Pub..
2d agoDJWANTED : Biotech Startups in New York City
2d agoDJJOHNSON & JOHNSON : Press Release : FDA expands approved use of Imbruvica for ch..
6d ago JOHNSON & JOHNSON : Untraceable implants adding to woes
6d ago Activist Elliott Management sets its sights on IPG
07/23 JOHNSON & JOHNSON : New Findings on Dermatology from Johnson & Johnson Summarize..
07/23 JOHNSON & JOHNSON : Announces Quarterly Dividend for Third Quarter 2014
07/23 JOHNSON & JOHNSON : Announces $5 Billion Share Repurchase Program
07/23 JOHNSON & JOHNSON : J&J buying back $5 billion worth of its shares
Advertisement
Chart
Duration : Period :
Johnson & Johnson Technical Analysis Chart | JNJ | US4781601046 | 4-Traders
Income Statement Evolution
Johnson _ Johnson : Income Statement Evolution
More Financials
Dynamic quotes  
ON
| OFF